{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:44:02Z","timestamp":1790304242764,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2013,9,26]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Lipoprotein\u2010associated phospholipase A2 (Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              ) levels are associated with coronary heart disease (\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              ) in healthy individuals and in patients who have had ischemic events.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              The Long\u2010term Intervention with Pravastatin in Ischemic Disease (\n              <jats:styled-content style=\"fixed-case\">LIPID<\/jats:styled-content>\n              ) study randomized 9014 patients with cholesterol levels of 4.0 to 7.0\u00a0mmol\/L to placebo or pravastatin 3 to 36\u00a0months after myocardial infarction or unstable angina and showed a reduction in\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              and total mortality. We assessed the value of baseline and change in Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              activity to predict outcomes over a 6\u2010year follow\u2010up, the effect of pravastatin on Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              levels, and whether pravastatin treatment effect was related to Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              activity change. Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              was measured at randomization and 1\u00a0year, and levels were grouped as quartiles. The prespecified end point was\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              death or nonfatal myocardial infarction. Baseline Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              activity was positively associated with\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              events (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.001) but not after adjustment for 23 baseline factors (\n              <jats:italic>P<\/jats:italic>\n              =0.66). In 6518 patients who were event free at 1\u00a0year, change in Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              was a significant independent predictor of subsequent\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              events after adjustment for these risk factors, including\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              cholesterol and\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              cholesterol changes (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.001). Pravastatin reduced Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              by 16% compared with placebo (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.001). After adjustment for Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              change, the pravastatin treatment effect was reduced from 23% to 10% (\n              <jats:italic>P<\/jats:italic>\n              =0.26), with 59% of the treatment effect accounted for by changes in Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              . Similar reductions in treatment effect were seen after adjustment for\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              cholesterol change.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Reduction in Lp\u2010\n              <jats:styled-content style=\"fixed-case\">PLA<\/jats:styled-content>\n              <jats:sub>2<\/jats:sub>\n              activity during the first year was a highly significant predictor of\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              events, independent of change in\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              cholesterol, and may account for over half of the benefits of pravastatin in the\n              <jats:styled-content style=\"fixed-case\">LIPID<\/jats:styled-content>\n              study.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.113.000360","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T03:08:36Z","timestamp":1382584116000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":39,"title":["Changes in Lipoprotein\u2010Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long\u2010term Intervention with Pravastatin in Ischemic Disease Study"],"prefix":"10.1161","volume":"2","author":[{"given":"Harvey D.","family":"White","sequence":"first","affiliation":[{"name":"Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Simes","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A. H.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Blankenberg","sequence":"additional","affiliation":[{"name":"University Heart Centre Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Barnes","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Marschner","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"},{"name":"Department of Statistics, Macquarie University, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"West","sequence":"additional","affiliation":[{"name":"University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Zeller","sequence":"additional","affiliation":[{"name":"University Heart Centre Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Colquhoun","sequence":"additional","affiliation":[{"name":"Greenslopes Hospital, Greenslopes, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nestel","sequence":"additional","affiliation":[{"name":"Baker IDI Heart and Diabetes Institute, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Keech","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital, Camperdown, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Cardiology and University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tonkin","sequence":"additional","affiliation":[{"name":"Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The LIPID Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj3380479"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000244681.72738.bc"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.10.065"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60319-4"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391902"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02258.x"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.612630"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc1002.105136"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01360-2"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010193431603"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000160551.21962.a7"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000191655.87296.ab"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.671420"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.05.006"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2011.180281"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31820376ac"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.366"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1870"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.771899"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.07.006"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.07.018"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/b138566"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.113.000360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:48:45Z","timestamp":1715597325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.113.000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,26]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9,26]]}},"alternative-id":["10.1161\/JAHA.113.000360"],"URL":"https:\/\/doi.org\/10.1161\/jaha.113.000360","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,26]]},"assertion":[{"value":"2013-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e000360"}}